Group 1 - Tianyue Advanced Technology Co., Ltd. (天岳先进) plans to list its H-shares on the Hong Kong Stock Exchange starting August 19, 2025, with a maximum offering price of HKD 42.80 per share [1] - The company intends to issue a total of 47,745,700 H-shares, with 2,387,300 shares available for public offering in Hong Kong and 45,358,400 shares for international offering [1] - Assuming the offering price of HKD 42.80 per share, the estimated net proceeds from the global offering will be approximately HKD 1,938.1 million, after deducting underwriting commissions and other estimated expenses [1] Group 2 - Tianyue Advanced was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on January 12, 2022, with an initial offering price of CNY 82.79 per share and a total of 42,971,100 shares issued [2] - The company is currently in a state of share price decline (破发状态) [2] - The total funds raised from the initial public offering amounted to CNY 35.58 billion, with a net amount of CNY 32.03 billion after deducting issuance costs, exceeding the original plan by CNY 1.203 billion [2] Group 3 - The total issuance costs for the initial public offering were CNY 354 million, with underwriting and sponsorship fees amounting to CNY 319 million [3]

中国经济网北京8月5日讯 海天味业（603288）（03288.HK）港股今日收报33.36港元，跌幅1.71%，创 上市以来收盘价新低。目前该股H股处于破发状态。 海天味业6月19日在港交所上市，当日盘中最低报36.05港元，跌幅0.69%，一度跌破发行价。最终发售 价及配发结果公告显示，海天味业全球发售项下的发售股份数目为279,031,700股H股（经计及发售量调 整权获悉数行使及视乎超额配股权行使与否而定），香港发售股份数目为55,279,900股H股（经重新分 配后调整），国际发售股份数目为223,751,800股H股（经计及发售量调整权获悉数行使、经重新分配后 调整以及视乎超额配股权行使与否而定）。 以今日收盘价33.36港元计算，较36.30港元的发行价已下跌8.1%，高瓴HHLR Advisors与HSG Growth （红杉中国）均浮亏。 海天味业的联席保荐人、整体协调人、联席全球协调人、联席账簿管理人及联席牵头经办人为中国国际 金融香港证券有限公司、高盛（亚洲）有限责任公司、摩根士丹利亚洲有限公司，联席账簿管理人及联 席牵头经办人为中银国际亚洲有限公司、工银国际证券有限公司、交银国际证券有 ...

Group 1 - The stock price of Arctech (688472.SH) fell by 3.56% to 8.93 yuan as of the market close on July 31, 2023, indicating that the stock is currently in a state of decline since its IPO [1] - Arctech was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on June 9, 2023, with an initial public offering (IPO) price of 11.10 yuan per share. The total number of shares issued before the full exercise of the over-allotment option was 541,058,824 shares, accounting for 15.00% of the total share capital post-issue [1] - After the full exercise of the over-allotment option, the total number of shares issued increased to 622,217,324 shares, representing 16.87% of the total share capital post-issue [1][2] Group 2 - The total amount of funds raised from the IPO was 600,575.29 million yuan before the exercise of the over-allotment option and 690,661.23 million yuan after the full exercise [1][2] - The net amount raised after deducting issuance costs was 572,782.43 million yuan before the over-allotment option and 662,845.46 million yuan after the full exercise [1][2] - The final net amount raised exceeded the original plan by 172,782.43 million yuan before the over-allotment option and 262,845.46 million yuan after the full exercise [2] Group 3 - The total issuance costs for the IPO were 27,792.86 million yuan before the over-allotment option and 27,815.77 million yuan after the full exercise, with underwriting and sponsorship fees amounting to 17,264.15 million yuan [3] - The actual controllers of Arctech are Xiaohua Qu and his spouse Han Bing Zhang, both of whom hold Canadian nationality [4]

中国经济网北京7月30日讯 君实生物(688180.SH)今日收报39.12元，跌幅4.59%。 君实生物于2020年7月15日在上交所科创板上市，发行数量为8713万股，发行价格为55.50元/股，保荐 机构、主承销商为中国国际金融股份有限公司，联席主承销商为国泰君安证券股份有限公司、海通证券 股份有限公司（2家公司现已合并为国泰海通证券股份有限公司）。 上市首日，君实生物股价最高报220.40元，此后该股一路震荡下滑，目前该股处于破发状态。 君实生物首发募集资金总额为48.36亿元，扣除发行费用后，募集资金净额为44.97亿元，较原计划多 17.97亿元。君实生物2020年7月8日发布的招股说明书显示，公司计划募集资金27.00亿元，分别用于创 新药研发项目、君实生物科技产业化临港项目、偿还银行贷款及补充流动资金。 君实生物上市发行费用为3.39亿元，其中保荐机构中金公司（601995）及联席主承销商国泰海通证券股 份有限公司获得保荐及承销费用3.20亿元，容诚会计师事务所（特殊普通合伙）获得审计、评估及验资 费用590.00万元，北京市嘉源律师事务所获得律师费用616.50万元。 君实生物2022年度向 ...

Core Viewpoint - The announcement reveals that shareholders of Saiwei Microelectronics (688325.SH) plan to reduce their holdings through a share transfer agreement, with a total of up to 15,505,310 shares (approximately 18.00% of the total share capital) to be transferred within six months from the announcement date [1] Group 1: Shareholder Reduction Plans - Wu Yuefeng Investment and its action group, including Beijing Yihe and Shanghai Lingguan, plan to reduce their holdings by a total of up to 15,505,310 shares [1] - Wu Yuefeng Investment intends to reduce its holdings by up to 9,778,735 shares (approximately 11.35% of the total share capital) from July 30, 2025, to January 29, 2026, due to personal funding needs [2] - Beijing Yihe plans to reduce its holdings by up to 3,348,874 shares (approximately 3.89% of the total share capital) during the same period for similar funding reasons [2] - Shanghai Lingguan aims to reduce its holdings by up to 2,377,701 shares (approximately 2.76% of the total share capital) within the same timeframe [2] Group 2: Company Background and Financials - Saiwei Microelectronics was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on April 22, 2022, with an initial offering price of 74.55 yuan per share [3] - The stock opened at 52.33 yuan on its first trading day, reflecting a decline of 29.81%, and has remained below the initial offering price [3] - The company raised a total of 1.491 billion yuan, with a net fundraising amount of 1.355 billion yuan, exceeding the original plan by 546 million yuan [4] - The funds raised are allocated for various projects, including battery management and power management chip development for consumer electronics and industrial applications, as well as working capital [5]

Core Viewpoint - Huaru Technology has been placed on the military procurement suspension list due to collusion in bidding, which is expected to impact its operations in the short term [1][2]. Group 1: Company Announcements - Huaru Technology announced on July 7 that it has been suspended from participating in air force procurement activities starting from July 4, 2025, due to collusion in bidding [1]. - This marks the third time Huaru Technology has been named for violations by the military procurement network [1]. - The company is taking the matter seriously and is preparing an appeal while also committing to improve its internal control systems [1]. Group 2: Financial Information - Huaru Technology was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on June 23, 2022, with an issuance of 26.37 million shares at a price of 52.03 yuan per share [2]. - The total funds raised from the initial public offering amounted to 1.372 billion yuan, with a net amount of 1.275 billion yuan, exceeding the original plan by 475 million yuan [2]. - The funds were intended for various projects, including a new generation combat system and a collaborative design and simulation testing platform [2]. Group 3: Stock Performance - Huaru Technology's stock is currently in a state of decline, having broken its initial offering price [2]. - The company announced a stock split of 10 shares for every 5 shares held, with a record date of May 31, 2023 [3].

Group 1 - The core point of the news is that Liu Yong, a senior executive of Xinrui Co., plans to reduce his shareholding due to personal financial needs, with a maximum reduction of 750,000 shares, accounting for 0.2971% of the company's total share capital [1][2] - The planned reduction period is from July 30, 2025, to October 29, 2025, and the shares to be reduced are from the pre-IPO holdings [2] - Xinrui Co. was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 27, 2021, with an issuance of 23.2 million shares at a price of 62.30 yuan per share, and the stock is currently trading below its IPO price [2][3] Group 2 - The total amount raised by Xinrui Co. during the IPO was 1.445 billion yuan, with a net amount of 1.352 billion yuan, exceeding the original plan by 670 million yuan [2] - The company has announced dividend plans, including a 4-for-10 bonus share and a pre-tax dividend of 5 yuan per share in 2023, 4 yuan in 2024, and 3 yuan in 2025 [3] - The total issuance costs for Xinrui Co. amounted to 93.8367 million yuan, with underwriting and sponsorship fees of 76.8819 million yuan paid to Minsheng Securities and Dongwu Securities [3]

Group 1 - The major shareholder, Phanmao (Shanghai) Investment Center, plans to reduce its stake in Derma by up to 18,462,500 shares, representing 4% of the total share capital, within three months after the announcement [1] - As of the announcement date, Phanmao holds 87,500,000 shares, accounting for 18.96% of Derma's total share capital, making it the second-largest shareholder [1] - The planned reduction will not lead to a change in control or significantly impact the company's governance structure or ongoing operations [1] Group 2 - Derma was listed on the Shenzhen Stock Exchange's ChiNext board on May 18, 2023, with a total public offering of 92,312,500 shares at a price of 14.81 yuan per share [2] - The total amount raised from the IPO was 136,714.81 million yuan, with a net amount of 123,110.94 million yuan after deducting issuance costs, which was 23,336.61 million yuan less than the original plan [2] - The IPO expenses totaled 13,603.87 million yuan, with the lead underwriter, China International Capital Corporation, receiving 8,967.71 million yuan in underwriting and advisory fees [2]

Core Viewpoint - The announcement of share reduction plans by shareholders of Anjiasi (688581.SH) indicates a strategic adjustment in their investment positions, with both shareholders planning to reduce their stakes by a total of 1,622,700 shares each, representing 2.0039% of the company's total shares [1][2] Group 1: Shareholder Reduction Plans - Shareholder Suzhou Yuansheng plans to reduce its holdings by up to 1,622,700 shares, with a maximum of 809,700 shares through centralized bidding and 813,000 shares through block trading [1] - Shareholder Hangzhou Tiantang Silicon Valley also plans to reduce its holdings by up to 1,622,700 shares, with the same distribution between centralized bidding and block trading [1] - The reduction period for centralized bidding is 90 natural days starting from 15 trading days after the announcement, while for block trading, it is 90 natural days starting from 3 trading days after the announcement [1] Group 2: Shareholding Structure - As of the announcement date, shareholder Suzhou Yuansheng holds 3,233,835 shares, accounting for 3.9934% of the total shares, with 2,309,882 shares from pre-IPO and 923,953 shares from the 2023 annual bonus shares [2] - Shareholder Hangzhou Tiantang Silicon Valley holds 1,622,700 shares, representing 2.0039% of the total shares, with 1,159,071 shares from pre-IPO and 463,629 shares from the 2023 annual bonus shares [2] - The pre-IPO shares held by these shareholders were released from restrictions and became tradable on May 20, 2024 [2] Group 3: IPO and Fundraising Details - Anjiasi raised a total of 182,032.60 million yuan from its IPO, with a net amount of 165,101.28 million yuan after deducting issuance costs, exceeding the original plan by 88,031.28 million yuan [3] - The funds raised are intended for projects including the production of 10 million medical endoscope devices, marketing network upgrades, and a minimally invasive medical device R&D center [3] - The total issuance costs amounted to 16,931.32 million yuan, with the lead underwriter, CITIC Securities, receiving 12,887.91 million yuan in fees [3] Group 4: Dividend Distribution - Anjiasi announced a cash dividend of 14.5 yuan (including tax) per 10 shares and a distribution of 4 bonus shares per 10 shares for the 2023 fiscal year, with the record date set for June 20 [4]

Core Viewpoint - The company *ST ChuanZhi (003032.SZ)* reported significant declines in its 2024 annual performance, with a notable drop in revenue and net profit, while showing some improvement in the first quarter of 2025. Financial Performance Summary - In 2024, the company achieved operating revenue of 246.66 million yuan, a decrease of 54.04% compared to 534.47 million yuan in 2023 [1][3] - The net profit attributable to shareholders was -133.92 million yuan, a decline of 956.85% from 15.63 million yuan in the previous year [1][3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -147.59 million yuan, down 752.85% from 22.61 million yuan in 2023 [1][3] - The net cash flow from operating activities was -87.21 million yuan, compared to -51.97 thousand yuan in the previous year, marking a significant decline [1][3] Q1 2025 Performance Summary - For the first quarter of 2025, the company reported operating revenue of 72.39 million yuan, an increase of 42.14% year-on-year [1][4] - The net profit attributable to shareholders was -5.36 million yuan, an improvement of 66.49% from -16.01 million yuan in the same period last year [1][4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -7.64 million yuan, a 70.58% improvement from -25.98 million yuan in Q1 2024 [1][4] - The net cash flow from operating activities was 6.92 million yuan, a significant increase of 116.50% compared to -41.97 million yuan in the previous year [1][4] Dividend Policy - The company plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves [2] Company Background - ChuanZhi Education was listed on the Shenzhen Stock Exchange on January 12, 2021, with an initial public offering of 40,244,750 shares at a price of 8.46 yuan per share [1][4] - The stock is currently trading below its initial offering price [4] - The total amount raised from the IPO was 340.47 million yuan, with a net amount of 291.65 million yuan after deducting issuance costs [4] Underwriting Information - The underwriting institution for the company is CITIC JianTou Securities Co., Ltd., with total underwriting fees amounting to 30.74 million yuan [5]